Cocrystal Pharma, Inc.
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $1.14
- 52-Week Range
- $0.76 – $2.03
- Market Cap
- $22.06M
- P/E (TTM)
- —
- EPS (TTM)
- -0.76
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 15.07
- PEG Ratio
- —
- Return on Equity
- -311.68%
- Return on Assets
- -96.07%
- Gross Margin
- 0.00%
- Operating Margin
- -3032.38%
- Profit Margin
- 0.00%
- Current Ratio
- 1.24
- Debt/Equity
- 1.28
- Total Debt
- $1.34M
- Free Cash Flow
- $-4.32M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $21.23M
Market Snapshot
About
Cocrystal Pharma, Inc. is a biotechnology company focused on the discovery and development of novel antiviral therapeutics. Headquartered in Bothell, Washington, the company uses proprietary structure-based drug design technologies to create first-in-class and best-in-class antiviral drugs. Cocrystal's pipeline includes antiviral programs targeting influenza, norovirus, hepatitis C virus, and coronaviruses including SARS-CoV-2. The company's technology platform enables the design of inhibitors that target viral replication mechanisms.